New selective tissue estrogenic activity regulator (STEAR) in menopausal therapy in Taiwan

Taiwanese Journal of Obstetrics and Gynecology

Volumn 44, Issue 4, 2005, Pages 327-331

  Chao, Kuan Chong ^a   Wang, Peng Hui ^a   Yen, Ming Shyen ^a   Chang, Ching Ying ^a   Juang, Chin Mu ^a   Twu, Nae Fan ^a   Wu, Hwa Shi ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Climacteric symptoms; Menopausal treatment; Selective tissue estrogenic activity regulator; STEAR; Tibolone

Indexed keywords

SELECTIVE TISSUE ESTROGENIC ACTIVITY REGULATOR; TIBOLONE; UNCLASSIFIED DRUG;

ACNE; ALLERGY; ARTICLE; BLEEDING; BODY WEIGHT; BREAST TENDERNESS; CLIMACTERIUM; DIZZINESS; DRUG EFFICACY; DRUG SCREENING; FEMALE; HEADACHE; HUMAN; INSOMNIA; LIBIDO; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENTAL INSTABILITY; PATIENT COMPLIANCE; STATISTICAL SIGNIFICANCE; TAIWAN; TREATMENT OUTCOME; WATER RETENTION; WEIGHT GAIN;

EID: 29544437300     PISSN: 10284559     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1028-4559(09)60165-0     Document Type: Article

References (27)

1. Kloosterboer HJ, Ederveen ACH. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (± progestogene) treatments. J Steroid Biochem Mol Biol 2003;83:157-65.
2. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 2001;76:231-8.
3. Bruce D, Robinson J, McWilliams S, Reddy M, Rymer J. Longterm effects of tibolone on mammographic density. Fertil Steril 2004;82:1343-7.
4. Berning B, Bennink HJ, Fauser BC. Tibolone and its effects on bone. Climacteric 2001;4:120-36.
5. Laan E, van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in post-menopausal women. Climacteric 2001;4:28-41.
6. Nathorst-Boos J, Hammar M. Effect on sexual life-a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas 1997;26:15-20.
7. Castelo-Branco C, Vicente JJ, Figueras F, et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 2000;34:161-8.
8. Rymer J, Robinson J, Fogelman I. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric 2002;5:390-8.
9. Chetrite G., Kloosterboer HJ, Pasqualini JR. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res 1997;17:135-40.
10. Gompel A, Siromachkova M, Lombet A, Kloosterboer HJ, Rostene W. Tibolone actions on normal and breast cancer cells. Eur J Cancer 2000;36:S76-7.
11. Volker W, Coelingh Bennink HJ, Helmond FA. Effects of tibolone on the endometrium. Climacteric 2001;4:203-8.
12. Kloosterboer HJ, Schoonen WG, Deckers GH, Klijn JG. Effects of progestagens and Org OD14 in in vitro and in vivo tumor models. J Steroid Biochem Mol Biol 1994;49:311-8.
13. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-59.
14. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.
15. Lundstrom E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Cynecol 2002;186:717-22.
16. Moore RA. Livial: a review of clinical studies. Br J Obstet Gynaecol 1999;106(Suppl 19):1-21.
17. Gulseren L, Kalafat D, Mandaci H, Gulseren S, Camli L. Effects of tibolone on the quality of life, anxiety-depression levels and cognitive functions in natural menopause: an observational follow-up study. Aust NZJ Obstet Cynaecol 2005;45:71-3.
18. Landgren MB, Helmond FA, Engelen S. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day. Maturitas 2005;50:222-30.
19. Bruce D, Robinson J, Rymer J. Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy. Climacteric 2004;7:261-6.
20. Vogelvang TE, van der Mooren MJ, Mijatovic V. Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications. Treat Endocrinol 2004;3:105-15.
21. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
22. Erratum in: Lancet 2003;362:1160.
23. Speroff L. The Million Women Study and breast cancer. Maturitas 2003;46:1-6.
24. Crosignani PG. Breast cancer and hormone-replacement therapy in the Million Women Study. Maturitas 2003;46:91-2.
25. Bundred NJ, Turner LE. Postmenopausal hormone therapy before and after breast cancer: clinical experiences. Maturitas 2004;49:S22-31.
26. Kroiss R, Fentiman IS, Helmond FA, et al. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. BJOG 2005;112:228-33.
27. Devogelaer JP. A review of the effects of tibolone on the skeleton. Expert Opin Pharmacother 2004;5:941-9.